Cytori Therapeutics, Inc. (CYTX) Reports Larger Q3 Loss
Cytori Therapeutics, Inc. (NASDAQ: CYTX) reported Q1 EPS of ($0.23), $0.08 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.36 million versus the consensus estimate of $3.21 million.